Mirakbarova Z, Turdikulova S. H. Targeted Hot Spot Sequencing of Uzbek Lung Cancer Patients. Biomed Pharmacol J 2021;14(1).

---

Manuscript received on :03-12-2020
Manuscript accepted on :04-03-2021
Published online on: 25-03-2021

---

Plagiarism Check: Yes
Reviewed by: Dr. Bhavana Gundavarapu  
Second Review by: Dr. Dini Damayanti  
Final Approval by: Dr. Ayush Dogra

---

How to Citeclose    |   Publication History close

 Views: (Visited 480 times, 1 visits today)    PDF Downloads: 344

Mirakbarova Z¹ and Turdikulova S. H²

¹Institute of biophysics and biochemistry at the National University of Uzbekistan named after Mirzo Ulugbek.

²Centre for advanced technologies under the Ministry of Innovative Development of the Republic of Uzbekistan.

Corresponding Author E-mail : zebyniso@gmail.com

DOI : https://dx.doi.org/10.13005/bpj/2138

Abstract

Objectives: Carcinoma of lung is a widespread multifactorial disease with a poor prognosis. Uzbek lung cancer patients screening for prevalent mutations, associated with cancer development by targeted next generation sequencing was the main objective of current research.

Materials and methods: Preparation of sequencing libraries was conducted using the Illumina Cancer Hot spot Panel v2 covering mutational hot spot regions of 50 cancer genes, from DNA extracted from formalin-fixed paraffin-embedded tumor samples of 10 patients. Sequencing was performed with the Mi Seq Next Generation Sequencing machine(NGS).

Results: Hot spot mutations data analysis revealed clinically benign mutations in allstudied samples, with 70% having 3 or more mutations stored in the COSMIC database.According to ClinVarFGFR3 gene was associated with Crouzon syndrome with acanthosis nigricans, PDGFRA, EGFR and TP53 gene mutations were corellated with Idiopathic hypereosinophilic syndrome, Lung cancer and Glioma susceptibility respectively.KIT and KDR gene mutations were, respectively, associated with Gastrointestinal stromal tumor and Hemangioma, capillary infantile. Synonymous variants in RET and HRAS genes, were associated congenital central hypoventilation and epidermal nevus syndrome respectively. EGFR gene mutations occurred exclusively in patients with adenocarcinoma G2. where as MET and BRAF mutations were identified in bronchioalveolar cancer samples.

Conclusion. In conclusion, particular polymorphisms and mutations affect treatment response and the toxicity level among patients with lung cancer, undergoing chemotherapy. Variety of SNPs were reported to have impact on disease outcomes of those patients, therefore they should be validated in an independent population, prior to being adopted for pre-personalised therapy screening.

Keywords

Lung Cancer; Multifactorial Disease

Introduction

Majority of cancer deaths worldwide both in men and women occur as an outcome of lung carcinoma.(1). Non-small cell lung cancer (NSCLC) represents the from 80 to 85% of diagnosed lung cancer cases(2,3). Despite having the same aetiology, types of lung cancer can vary on molecular level: epigenetic changes, protein expression, mutations etc, which are reported as diagnostic markers and can influence the therapy outcome Although platinum based doublet therapy has been used as the standard treatment for late stages for many years, accumulating evidence suggests that lung non small cell lung cancer patients with activated EGFR, KRAS, BRAF and some other genes represent positive outcome, while treated with targeted therapy methods.(4,5). Thus, it is important to identify the mutation status of NSCLC patients prior to treatment tactic selection.Advanced stages of lung cancer are currently unpreventable.Clinical assays define using molecular subtype, clinical and histological features of cancer as a basis of therapy methods [1]. Large-scale investigations are proving lung cancer heterogeneity and its development into progressive disease [2, 3] and, paired with the dramatical advancement of therapy methods, illustrate the need for more complex diagnostics in cancer management [4].

Diagnostics based on next generation sequencing (NGS) are creating an opportunity for researchers and clinicians to identify specific modification occurring in tumor cells. Basically, identifying pathologic transformation on gene and protein level enables clinicians to diagnose oncologic diseases on early stages as well as predict therapy responses more exactly.At the meantime current methods comprise of realtime polymerase chain reaction (PCR) and Sanger sequencing, where each selected region of studied gene in a given sample is studied on separate basis. Sanger sequencing method has yet several challenges to overcome while detecting somatic mutations, associated with cancer development. These mutations are detected at low prevalence, due to specific localisations features of the tumor or the variations in mixture rates of normal and tumor tissues in studied samples, therefore, require reliable DNA library preparation and highly sensitivemethods for successful detection. To accomplish this, highly sensitive next-generation sequencing, with its remarkable throughput, is dramatically entering the clinical testing area. However to date, limited use of this method in clinical diagnostics is observed[5]. Primary lung, colon, pancreatic and other cancers were shown to be conveniently detected by theAmpliSeq Cancer Hotspot Panel [7],

Materials and methods

Subjects

The subjects were recruited from people, undergoing treatment in the Department of Thoracic surgery National Cancer Center of Uzbekistan. 20 people were asked to participate and 12 accepted. Subjects with the history of small cell carcinoma and tuberculosis were excluded from the study. Finally, the baseline data of 10 Uzbek adults(7 males and 3 females), 38-66 years of age were analyzed in this study. Written informed consent in a form approved by the Ethics Committee under the Ministry of Health of the Republic of Uzbekistan was obtained from all subjects for participation in the current study. Geno typing and data analyses were performed according to lab protocols approved by the same Ethics Committee. Patients with histologically confirmed lung adenocarcinomas and squamous cell carcinoma of different stages were eligible for enrolment in his study.All patients provided clinic-pathological as well as demographic data, including age at diagnosis, gender, nationality, profession, workplace, place of birth,concomitant diseases history, tumor stage, prior therapy, family history. Formalin fixed paraffin embedded tumor tissue specimens, previously studied for adequacy via histopathological assessment were included in this study.

DNA extraction

Tumor cells from archive FFPE tissue samples were initially micro dissected manually. DNA from10 FFPE tissue slides was extracted according to Relia Prep™ FFPE gDNA Mini prep System Promega protocol at the laboratory of Biotechnology Centre for advanced Technologies under the Ministry of Innovative development of the Republic of Uzbekistan. Assessment of DNA quality and quantity was conducted using a Shimadzu BioSpec-nano Micro-volume UV-Vis Spectrophotometer (Japan) and Qubit dsDNA HS Assay Kit and a Qubit 2.0 fluorometer. All DNA samples were aliquoted and stored at−20 °C until analysis.

Library Preparation and Quality Control

Illumina AmpliSeqCancer Hotspot Panel v2,containing probes to generate 207 amplicons from 50genes, associated with cancer,to identify around 2800 mutations in hotspot regions was used to prepare sequencing amplicon libraries. The amplicons of target regions were generated using 207 oligonucleotide pairs, during thermocycling in GeneAmp® PCR-amplifier Verity AB. Further target amplicons were partially digested to form and phosphorylate sticky ends to facilitate bar-coded adapter ligation. The amplicons were flanked with index sequences, during multiplex PCR to create unique index combinations for dual index sequencing. After library clean-up, quality of library was assessed on a Qubit dsDNA HS Assay Kit and a Qubit 2.0 fluorometer. Afterwards, libraries were reamplified to ensure required quantity for Illumina sequencing with further two round clean-up. In order to provide optimum cluster density on the flow cell the library was checked on Qubit 2.0 fluorometer, normalized, diluted to 2.8ng/μl, before pooling equal volumes for final sequencing library generation, after which libraries were quantified and diluted to starting concentration. MiSeq instrument was used for pooled library sequencing applying a 2 150 paired-end sequencing design

Data analysis

Raw data was processed in FASTQ Generation Version: 1.0.0 within Base Space to generate fastq file. The IGV16 (Broad Institute, Cambridge, Massachusetts) was applied to align paired-end fastq format raw reads to the hg19 reference genomeand produce VCF files. Illumina Variant Studio version 1.0 (Illumina) vs Annovar were used for variants annotation.

Variant effect predictor(VEP) on ENSEMBLE and CRAVAT version 4.3 (http://hg19.cravat.us/CRAVAT/)  was implemented for identification of variants from aligned reads. Variants representing a global minor allele frequency more than 0.1% were excluded from further studies, being considered as common SNPs as well as non-coding variants.

Results

Molecular-genetic analysis was finalised, and reports formed in 30 days, after receiving agreement consent from patients to be enrolled in this study.Variant Effect Predictor was used to perform annotation, by classifying variants into 8 various classes (“Frame Shift Insertion”, “Missense Mutation”, “Frame Shift Deletion”,“In Frame Insertion”, “In Frame Deletion”, “Nonsense Mutation”and“Splice Site”). Variants having allele frequency less than 0.05% and SIFT score <0.05 (Deleterious) were retained. All patients, included in the study had mutations in genes, responsible explicitly or implicitly for carcinogenesis and drug sensitivity and involved in Hot Spot Cancer v2 panel. Overall mutations in 18 genes, 11 of which were reported as oncogenes and 7 as tumor suppressor genes were identified.All the mutations identified except 5 appeared to be initiating aminoacid change in coded proteins.

Hot-spot mutationswere identified in below mentioned genes during data analysis: ALK, APC, BRAF, ERBB4, EGFR, FGFR1, FBXW7, HRAS, FGFR3, KIT, KDR, MET, PDGFRA, PTEN, RET, SMAD4, SMARCB1, TP53, illustrated in COSMIC database.

Figure 1: Illustration of genes with hot spot mutations in Uzbek NSCLC patients. Click here to view figure

Identified SNPs population minor allele frequency range was from 0,06% to 0,95% according to the 1000 Genomes database.

Table 1: Single-Nucleotide Polymorphisms  inAmpliSeq Cancer Hotspot Panel with MAF greater than or equal to 0.05%.

*Minor allele frequency (MAF) according to the 1000 Genomes database

All participants underwent adjuvant chemotherapy as standard treatmentmethod prior to analysis. Mutations in PDGFRA, FGFR3, APC, EGFR and TP53genes being the most frequently were revealed in 70% of studied samples. According to ClinVar database rs7688609 in FGFR3 gene was associated with Crouzon syndrome with acanthosis nigricans, rs1873778 in PDGFRA gene, rs1050171 in EGFR gene and rs1042522 in TP53gene were associated with Idiopathic hypereosinophilic syndrome, Lung cancer and Glioma susceptibility respectively. The second and third most common mutations with 50% and 60% were reported to bemissense variants rs3822214 and rs1870377 in KIT and KDR genes respectively, associated with Gastrointestinal stromal tumor and Hemangioma, capillary infantile. Synonymous variants in rs1800861 in  RET and rs12628 in HRAS genes, giving association with Congenital central hypoventilation and Epidermal nevus syndrome respectively came fourth with the index of 40%. Worth noting that each participant of this study had at least one variant, associated with lung cancer development, in addition, involved in drug metabolism.

Discussion

Lung cancer is multi factorial disease, occurring in majority cases because of genetic translocations in organism. Each type of lung cancer has specific treatment methods, based on histological subtype, stage, aetiology. Over the past decade, targeted therapy of lung cancer has become one of the standard methods of treatment for non-small cell lung cancer. Mutational spectra identified during the research was found to be potential targets in the implementation of targeted therapy.Validation of identified EGFR mutations was conducted by classic mutant enriched PCR method, showing 96% concordance, proving trustfulness of Hot Spot Cancer Sequencing results.Study of c.2361A>G mutation in patients with colorectal, breast and lung cancer revealed better clinical outcome after anti-EGFR treatment[3].The frequency of missense mutation in EGFR genec.2361A>G, leading glycine to histidine change in amino acid strain of coded protein, was rather high than reported in other studies, researching European (4,9-15%)[2,6,7,12,15]and Asianlung cancer patients(3,8-49,1%), however no correlation was identified between the mutation status and patients’ characteristics of age, gender, smoking history[16, 17].Although, several studies were conducted showing the role of exon 20 EGFR mutation in chemotherapy response, it wasn’t included in PharmGKB database up to date.CC geno type in rs1042522 of TP53 gene was reported as one of the risk factors, leading to lung cancer development in Bangladeshi population[4]. According to Pharm GKB, rs1042522 is associated with decreased response to capecitabine and paclitaxel, in patients with stomach neoplasms, while patients with ovarian neoplasms, carrying this mutation, suffered from more severe form of Neutropenia while being treated with cyclophosphamide and cisplatin. According to 1000Genomes, studies conducted in aggregated populations showed the frequency of TP53 mutations from 30 to 68%[9]. In our study the frequency of TP53 mutation was higher than reported elsewhere, although further studies are yet to be conducted. Regarding the study of rs1873778 in PDGFRA gene and rs7688609 in FGFR3, which was present in 70% of studied samples, association with cervical adenosquamous carcinoma and colorectal cancer to add withafatinib resistance in non-small cell lung cancer patients was reported[1]. KIT gene mutation rs3822214 identified in studied samples was shown to have clinical significance in partial albinism, gastrointestinal stromal tumor, hereditary cancer-predisposing syndrome, mastocytosis, chronic myelogenous leukemia[14]. According to results of multivariate analysis, conducted in 163 patients with various types of cancer,major homozygous rs1870377 genotype of KDR had negative effects on both TTF and OS, when compared to the effects of the heterozygous or minor homozygous genotypes, while being treated with sunitinib as an complementary therapy[10], in addition kinase insert domain receptor polymorphisms are associated with the increased protein concentration in serum plasma and correlate with an increased risk of stomach, lung and breast neoplasms progression[8,11,13].

Conclusion

In conclusion, particular polymorphisms and mutations affect treatment response and the toxicity level among patients with lung cancer, undergoing chemotherapy. Variety of SNPs were reported to have impact on disease outcomes of those patients therefore, they should be validated in an independent population, prior to being adopted for pre-personalised therapy screening.

Availability of data and materials

The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request.

Acknowledgement.

We thank Professor M.TillyashakhovDirector of the Republic Specialized Scientific Practical Medical Centre of Oncology and Radiology and his vice-director Professor A.A. Yusupbekov and the staff of the departments of Thoracic surgery and Pathomorphology for clinical data and sample collection support and D. Dalimova the head of the laboratory of Biotechnology Centre for Advanced Technologies under the Ministry of Innovative Development of the Republic of Uzbekistan and the staff of the laboratory for practical support in organizing the initial sample preparation works. Authors are grateful to the Ministry of Innovative Development of the Republic of Uzbekistan for providing funding opportunity to conduct this research.

Conflict of interest

Authors of the manuscript Mirakbarova Z and TurdikulovaSh don’t have a potential conflict of interest to declare.
The funders of current research had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and have no potential conflict of interest to declare.

Funding Source

This research was supported by Scientific Research Projects PZ-2014-0915210258 and MU-PZ-20171025473, funded by the Ministry of Innovative Development of the Republic of Uzbekistan. The funders had no role in study design, data collection and Author’s contributions

References

1. AdhemarLongatto-Filho 1, Pinheiro C, Martinho O, Marise A, Moreira R, Luiz F, Ribeiro J, Queiroz G, Schmitt F, Baltazar F, Rui M Reis Molecular Characterization of EGFR, PDGFRA and VEGFR2 in Cervical Adenosquamous Carcinoma. BMC Cancer 2009 Jun 29;9:212. doi: 10.1186/1471-2407-9-212.
   CrossRef
2. Boch C, Kollmeier J, Roth A, et al., The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data forcentral Europe from a cohort study, BMJ Open 3 (2013) Print 2013, http://dx.doi.org/10.1136/bmjopen,2013-002560
   CrossRef
3. Bonin, S., Donada, M., Bussolati, G., Nardon, E., Pichler, M., Chiaravalli, A. M., …Stanta, G. (2016). The EGFR synonymous polymorphism rs1050171 predicts responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. European Journal of Cancer, 61, S181–S182.doi:10.1016/s0959-8049(16)61643-x
   CrossRef
4. Chowdhury MK, Moniruzzaman M, Emran AA, Mostafa MG, Kuddus RH, Uddin MA. TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. Asian Pac J Cancer Prev. 2015;16:3493–98. doi: 10.7314/APJCP.2015.16.8.3493.
   CrossRef
5. Dong L., Wang W., Li A., Kansal R., Chen Y., Chen H., Li X. Clinical next generation sequencing for precision medicine in cancer. 2015.
   CrossRef
6. Gahr S, Stoehr R, Geissinger E, et al., EGFR mutational status in a large seriesof Caucasian European NSCLC patients: data from daily practice, Br. J. Cancer109 (2013) 1821–1828.
   CrossRef
7. Hogdall, P. Clementsen, et al., The prevalence of EGFR mutationsin non-small cell lung cancer in an unselected Caucasian population, APMIS123 (2015) 108–115
   CrossRef
8. Langsenlehner, U., Hofmann, G., Renner, W., Gerger, A., Krenn-Pilko, S., Thurner, E.M., Krippl, P. and Langsenlehner, T. (2015) Association of Vascular Endothelial Growth Factor: A Gene Polymorphisms and Haplotypes with Breast Cancer Metastases. ActaOncologica, 54, 368-376.
   CrossRef
9. Liu X, Lin X, Wang C, et al., Association between smoking and p53mutation in lung cancer: a meta-analysis, Clin. Oncol. (R. Coll. Radiol.) 26(2014) 18–24.
   CrossRef
10. Maeng C, Yi J, Lee J, Hong J, Choi M, Jung H, et al. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib. Anticancer research. 2013;33(10):4619–26. Epub 2013/10/15.pmid:24123039.
11. N Naykoo, Dil-Afroz, RRasool, S Shah, AAhangar, I Bhat, I Qasim, M Siddiqi, Z Shah.Single Nucleotide Polymorphisms, Haplotype Association and Tumour Expression of the Vascular Endothelial Growth Factor (VEGF) Gene with Lung Carcinoma. Gene, 608, 95-102.
    CrossRef
12. Ramlau, T. Cufer, P. Berzinec, et al., Epidermal growth factor receptormutation-positive non-small-cell lung cancer in the real-world setting incentraleurope: the INSIGHT study, J. Thorac. Oncol. 10 (2015) 1370–1374.
    CrossRef
13. Sa-Nguanraksa, Kooptiwut D, Chuangsuwanich S, Pongpruttipan T, Malasit T, Charoenrat P and O, (2014) Vascular Endothelial Growth Factor Polymorphisms Affect Gene Expression and Tumor Aggressiveness in Patients with Breast Cancer. Molecular Medicine Reports, 9, 1044-1048.
    CrossRef
14. Siqueira E, de Sousa S, Franca J, et al. Targeted next-generation sequencing of glandular odontogenic cyst: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124:490-494.
    CrossRef
15. Smits A, Kummer J, Hinrichs J, et al., EGFR and KRAS mutations in lungcarcinomas in the Dutch population: increased EGFR mutation frequency inmalignant pleural effusion of lung adenocarcinoma, Cell Oncol. 35 (2012)189–196.[18] B.G. Skov, E.
    CrossRef
16. Xu S, Duan Y, Lou L, et al. Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay. Oncology Letters 2016;12:4238–44.
    CrossRef
17. Y Wang, W Bao, H Shi, Y Zhang.Epidermal Growth Factor Receptor Exon 20 Mutation Increased inPost-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients’ Blood Samples.TranslationalOncology6 (2013) 4: P. 504–510.
    CrossRef